Loading
A phase 1/2 trial of Epcoritamab, Rituximab, Cyclophosphamide in diffuse large b-cell lymphoma and follicular lymphoma, run by Genmab, active and no longer recruiting.
Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL) is a phase 1/2 interventional study registered as NCT04542824 by Genmab, with 78 participants enrolled, started 2020-08-20 and due to reach its primary completion in 2027-09. Interventions recorded: Epcoritamab (monotherapy), Epcoritamab, Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, Gemcitabine and oxaliplatin, Epcoritamab (maintenance). Conditions listed: Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma, Follicular Lymphoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Epcoritamab, Genmab, Prednisone, Vincristine.
Shares Epcoritamab, Genmab, Prednisone, Vincristine.
Shares Genmab, Prednisone, Vincristine, Rituximab.
Shares Epcoritamab, Genmab, Prednisone, Vincristine.
Shares Epcoritamab, Genmab, T-cell engagers (bispecific), Follicular lymphoma.
Shares Prednisone, Vincristine, Rituximab, T-cell engagers (bispecific).
Shares Prednisone, Vincristine, Rituximab, T-cell engagers (bispecific).
Shares Prednisone, Vincristine, Rituximab, T-cell engagers (bispecific).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/